Analyst Price Targets — NERV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 1, 2025 8:10 pm | — | Jefferies | $5.00 | $3.80 | TheFly | Minerva price target raised to $5 from $3 at Jefferies |
| August 7, 2024 6:09 am | Douglas Tsao | H.C. Wainwright | $5.00 | $2.94 | TheFly | Minerva price target lowered to $5 from $7 at H.C. Wainwright |
| May 2, 2024 6:49 am | Douglas Tsao | H.C. Wainwright | $7.00 | $2.40 | StreetInsider | Minerva Neurosciences (NERV) PT Lowered to $7 at H.C. Wainwright |
Latest News for NERV
Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript
BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, February 3, 2026 at 10:30 AM ET featuring Gregory Strauss, PhD (Franklin Professor of Psychology, University…
UCB (OTCMKTS:UCBJY - Get Free Report) and Minerva Neurosciences (NASDAQ: NERV - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations. Valuation and Earnings This table compares UCB and Minerva
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NERV.
U.S. House Trading
No House trades found for NERV.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.